Nuvation Bio director gets 74,813 stock options

Cui Xiangmin reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Cui Xiangmin reported acquisition or exercise transactions in this Form 4 filing.

Nuvation Bio Inc. reported that director Xiangmin Cui received a grant of stock options covering 74,813 shares on February 27, 2026. The options have a grant price of $0.00 per share and represent a right to buy company stock rather than immediate ownership.

According to the terms, the option vests as to 1/24 of the shares on the one-month anniversary of January 1, 2026, and then monthly over the following 23 months, as long as Cui remains in continuous service on each vesting date. After this grant, Cui holds 74,813 stock options directly.

Insider Trade Summary

Grant/Award: 74,813 shares

Grant/Award 1 txn

Insider Cui Xiangmin

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	74,813	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 74,813 contracts (Direct)

Footnotes (1)

1. F1. Option vests as to 1/24 of the shares on the one month anniversary of 1/1/2026, monthly thereafter over the following 23 months, subject to Reporting Person's continuous service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nuvation Bio (NUVB) report for Xiangmin Cui?

Nuvation Bio reported a stock option grant to director Xiangmin Cui for 74,813 shares. The award was recorded on February 27, 2026, and represents a right to buy shares rather than an immediate share purchase.

How many Nuvation Bio (NUVB) stock options were granted to Xiangmin Cui?

Xiangmin Cui was granted stock options for 74,813 Nuvation Bio shares. These options were reported as a single derivative transaction, with 74,813 options held directly following the grant, according to the Form 4 filing.

What is the vesting schedule of Xiangmin Cui’s Nuvation Bio (NUVB) stock options?

The option vests 1/24 of the shares on the one-month anniversary of January 1, 2026. The remaining shares vest monthly over the next 23 months, contingent on Cui’s continuous service on each vesting date.

What was the exercise price of the Nuvation Bio (NUVB) stock options granted to Xiangmin Cui?

The reported transaction shows an exercise price of $0.00 per share for the stock options. This indicates a grant or award, rather than a purchase in the open market, as disclosed in the Form 4 data.

Is Xiangmin Cui’s ownership in Nuvation Bio (NUVB) direct or indirect after this option grant?

After the grant, Xiangmin Cui’s reported ownership of these stock options is direct. The Form 4 lists 74,813 derivative securities held with a direct ownership code and no intermediary entity described.

Does the Nuvation Bio (NUVB) Form 4 indicate any stock sales by Xiangmin Cui?

No stock sales are indicated for Xiangmin Cui in this Form 4. The filing reports only an acquisition of derivative securities through a stock option grant, with no dispose or sell transactions listed in the summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 07:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cui Xiangmin

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.91	02/27/2026		A		74,813		(1)	02/26/2036	Class A Common Stock	74,813	$0	74,813	D

Explanation of Responses:

1. Option vests as to 1/24 of the shares on the one month anniversary of 1/1/2026, monthly thereafter over the following 23 months, subject to Reporting Person's continuous service on each such vesting date.

	/s/ Stephen Dang, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.